Avas CV Capsules (Atorvastatin + Clopidogrel)

• Composition :
  Each capsule contains Atorvastatin 10mg / 20mg and Clopidogrel 75mg.
• Indications :
  For the treatment of dyslipidemia associated with atherosclerotic arterial disease with risk of myocardial infarction, stroke or peripheral vascular disease.
• Pharmacodynamics :
  Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. With ultracentrifugation, these complexes separate into HDL, IDL, LDL, and VLDL fractions. Clopidogrel is a platelet aggregation inhibitor. Clopidogrel is metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
• Dosage and administration :
  One tablet, once daily.
• Contraindications :
  Contraindicated in hypersensitivity to the drug substance or any component of the product, pathological bleeding such as peptic ulcer or intracranial hemorrhage. Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels, Women who are pregnant or may become pregnant, Nursing mothers
• Precautions and warnings :
  Atorvastatin - Myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis, Liver Dysfunction, patients with recent stroke or TIA, endocrine function, hepatic impairment. Clopidogrel- Prolongs bleeding time and therefore should be used with caution in patients who may be at risk of increased bleeding. Premature discontinuation increases risk of cardiovascular events.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy category X, contraindicated in women who are or may become pregnant, Nursing is not recommended, long-term efficacy in children has not been established.
• Drug interactions :
  Atorvastatin- Digoxin: Patients should be monitored appropriately. Cyclosporine: Do not exceed 10 mg atorvastatin daily. Clarithromycin, itraconazole, HIV protease inhibitors: Caution when exceeding doses > 20 mg atorvastatin daily. Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased. Rifampin should not be simultaneously co-administered with Atorvastatin.. Clopidogrel- Avoid concomitant use with NSAIDs and Warfarin should be co-administered with caution.
• Adverse reactions :
  The most common adverse events nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, bleeding.
• Therapy Area :
  Lipid Lowering agents